Oral Metronidazole

Preclinical

DDouglas Kwon

Oral Metronidazole is one of 21 therapeutic programs targeting Bacterial Vaginosis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Bacterial VaginosisRecruiting

Bacterial VaginosisPreclinical

Recruiting

Competition

Competitive Landscape

65 competitors in Bacterial Vaginosis

#DrugCompanyPhaseTrials

Flagyl

DDePuy Orthopaedics

Approved

25 2

Acanya

Pfizer

Approved

3 3

Decadron

AAspen Global Incorporated

Approved

—4

Amoxil

GGlobal Antibiotics Research and Development Partnership

Mycostatin

N-Acetyl Cyteien

1 7

Tindamax

MMission Pharmacal

Phase 3

3 8

Conventional

PPopulation Health Research Institute

Phase 3

1 9

Lactoferrin

UUniversità degli Studi di Ferrara

Phase 3

1 10

Lactoserum

Sanofi

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

PreclinicalRecruiting

Bacterial Vaginosis

NCT04046900

Clinical

Trials by Indication[1]

Bacterial Vaginosis1 trial

Vaginal Microbiota Transplant to Promote Lactobacillus-dominant Cervicovaginal Communities

Recruiting·DDouglas Kwon·Preclinical·NCT04046900·62 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Oral Metronidazole. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Oral Metronidazole. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Douglas Kwon company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: DDouglas Kwon

Oral Metronidazole

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Bacterial Vaginosis1 trial

References

Drug Info

Quick Facts

Related News